FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to overcome such drug resistance. We es...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Azuma, Koichi, Kawahara, Akihiko, Sonoda, Kahori, Nakashima, Kazutaka, Tashiro, Kousuke, Watari, Kosuke, Izumi, Hiroto, Kage, Masayoshi, Kuwano, Michihiko, Ono, Mayumi, Hoshino, Tomoaki
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2014
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171601/
https://ncbi.nlm.nih.gov/pubmed/25115383
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados